Ignacio Tusquets
YOU?
Author Swipe
View article: Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study Open
In this post hoc analysis, niraparib efficacy was similar across PDS and NACT/IDS subgroups. Patients who had NACT/IDS and VRD had the highest reduction in the risk of progression with niraparib maintenance.
View article: Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Open
Background Derived neutrophil-to-lymphocyte ratio (dNLR) is a biomarker associated with clinical outcome in breast cancer (BC). We analyzed the association of dNLR with pathological complete response (pCR) in triple-negative BC (TNBC) pati…
View article: 4CPS-273 Does age really matter on the prevalence of drug–drug interactions with endovenous chemotherapy?
4CPS-273 Does age really matter on the prevalence of drug–drug interactions with endovenous chemotherapy? Open
Background and importance Cancer patients receive multiple medications, exposing them to an increased risk of drug–drug interactions (DDI). Moreover, DDIs represent an escalating concern for older adults. Screening for DDI is not generally…
View article: Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial
Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With <i>ERBB2/HER2</i> -Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial Open
clinicaltrials.gov Identifier: NCT01822314.